Who are Victoza's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Adlyxin, Albugon, Byetta, Byetta, Mounjaro, Victoza.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/liraglutide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Victoza — Competitive Intelligence Brief

Victoza (liraglutide) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: GLP-1 Receptor Agonist [EPC]. Area: Metabolic.

marketed GLP-1 Receptor Agonist [EPC] Glucagon-like peptide 1 receptor Metabolic Live · refreshed every 30 min

Target snapshot

Victoza (liraglutide) — Novo Nordisk.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Victoza TARGET	liraglutide	Novo Nordisk	marketed	GLP-1 Receptor Agonist [EPC]	Glucagon-like peptide 1 receptor
Adlyxin	LIXISENATIDE	Sanofi-Aventis Us Llc	marketed	Insulin Analog [EPC]	Glucagon-like peptide 1 receptor	2016-01-01
Albugon	ALBIGLUTIDE	GSK	marketed	GLP-1 Receptor Agonist	Glucagon-like peptide 1 receptor	2014-01-01
Byetta	EXENATIDE	AstraZeneca	marketed	GLP-1 Receptor Agonist [EPC]	Glucagon-like peptide 1 receptor	2005-01-01
Byetta	Byetta	AstraZeneca	marketed	GLP-1 Receptor Agonist [EPC]	Glucagon-like peptide 1 receptor	2005-01-01
Mounjaro	Mounjaro	Nicholas Skertich	marketed		Gastric inhibitory polypeptide receptor, Glucagon-like peptide 1 receptor
Victoza	Victoza	Hanmi Pharmaceutical Company Limited	marketed		Glucagon-like peptide 1 receptor

Recent regulatory actions (last 90 days)

2026-02-24 — Victoza · FDA · approved · US · Novo Nordisk

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-08-18 — Byetta · 9884092 · US
2026-08-18 — Byetta · 8906851 · US
2026-08-18 — Byetta · 8329648 · US
2027-02-18 — Byetta · 9884092*PED · US
2027-02-18 — Byetta · 8906851*PED · US
2027-02-18 — Byetta · 8329648*PED · US
2027-06-20 — Byetta · 8501698 · US
2027-11-12 — Byetta · 8758292 · US
2027-12-20 — Byetta · 8501698*PED · US
2028-01-12 — Byetta · 8216180 · US
2028-03-21 — Byetta · 8361972 · US
2028-03-25 — Byetta · 9320853 · US
2028-03-25 — Byetta · 8439864 · US
2028-05-12 — Byetta · 8758292*PED · US
2028-07-12 — Byetta · 8216180*PED · US
2028-09-21 — Byetta · 8361972*PED · US
2028-09-25 — Byetta · 9320853*PED · US
2028-09-25 — Byetta · 8439864*PED · US
2029-02-04 — Byetta · 8827963 · US
2029-05-19 — Byetta · 8690837 · US
2029-08-04 — Byetta · 8827963*PED · US
2029-11-19 — Byetta · 8690837*PED · US
2030-01-07 — Byetta · 8998876 · US
2030-01-18 — Byetta · 8721615 · US
2030-07-07 — Byetta · 8998876*PED · US
2030-07-18 — Byetta · 8721615*PED · US
2030-10-04 — Byetta · 8895033 · US
2031-04-04 — Byetta · 8895033*PED · US
2037-01-09 — Victoza · 9968659 · Method of Use · US
2037-07-09 — Victoza · 9968659*PED · Compound · US

Sponsor landscape (GLP-1 Receptor Agonist [EPC] class)

AstraZeneca · 2 drugs in this class
Novo Nordisk · 2 drugs in this class
Eli Lilly · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Victoza — Competitive Intelligence Brief. https://druglandscape.com/ci/liraglutide. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab